This NDC is on FDA's drug shortage list (posted Dec 15, 2021)

Reported reason: Demand increase for the drug

Product Information

DEPO-MEDROL 40 MG/ML VIAL is a brand product labeled by Pharmacia & Upjohn Company LLC, priced at $6.8271 per ML under NDC 00009307301. Its NADAC has been published 423 times since Nov 28, 2013.

FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The Low Outlier badge above means this manufacturer's average price in the methylprednisolone acetate market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

DEPO-MEDROL 40 MG/ML VIAL

methylprednisolone acetate
$6.8271per ML
Low Outlier

Strength

40 mg/mL

NDC

00009307301

Classification

Brand

Dosage Form

INJECTION, SUSPENSION

Route

INTRA-ARTICULAR; INTRALESIONAL; INTRAMUSCULAR; SOFT TISSUE

Effective Date

9/23/2026

Active Ingredients

METHYLPREDNISOLONE ACETATE

Approval Type

New Drug (NDA)

FDA Application

NDA011757

FDA Approved

Before 1982

TE Code

AB

On Market Since

5/28/1959

Pharmacological Classes

Corticosteroid Hormone Receptor Agonists
Corticosteroid

Price Statistics

The NADAC for DEPO-MEDROL 40 MG/ML VIAL has been published 423 times since Nov 28, 2013, and over the history we have for it it has risen 23.3%. The table below summarizes its recorded NADAC range and movement.

Current price$6.8271 per ML
All-time high$11.0670 (Jul 11, 2018)
All-time low$5.0640 (Nov 18, 2015)
52-week high$7.5767
52-week low$6.6865
Median price$7.2000
Average price$7.6783
Largest weekly change+56.5% (Feb 18, 2015)
Weeks tracked423
Tracking sinceNov 28, 2013

Price History

1W

0.0%

1M

-0.8%

3M

-3.6%

6M

-6.3%

1Y

+1.4%

3Y

-32.5%

5Y

-32.5%

All

+23.3%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 15% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of DEPO-MEDROL 40 MG/ML VIAL?

The current National Average Drug Acquisition Cost (NADAC) for DEPO-MEDROL 40 MG/ML VIAL, manufactured by Pharmacia & Upjohn Company LLC, is $6.8271 per ML (NDC 00009307301), effective Sep 30, 2026.

How has the price of DEPO-MEDROL 40 MG/ML VIAL changed over time?

Over the history we have for it, the NADAC for DEPO-MEDROL 40 MG/ML VIAL has risen 23.3%. It has been tracked across 423 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for DEPO-MEDROL 40 MG/ML VIAL?

Since Nov 28, 2013, the NADAC for DEPO-MEDROL 40 MG/ML VIAL has ranged from a low of $5.0640 (Nov 18, 2015) to a high of $11.0670 (Jul 11, 2018), with a median of $7.2000 per ML.

Are there cheaper alternatives to DEPO-MEDROL 40 MG/ML VIAL?

Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METHYLPREDNISOLONE 400 MG/10 ML, is $5.8078 per ML — about 15% below DEPO-MEDROL 40 MG/ML VIAL.

Who manufactures DEPO-MEDROL 40 MG/ML VIAL?

DEPO-MEDROL 40 MG/ML VIAL (NDC 00009307301) is labeled by Pharmacia & Upjohn Company LLC, and CMS classifies it as a brand product.

Is DEPO-MEDROL 40 MG/ML VIAL in shortage?

Yes — NDC 00009307301 is currently listed in FDA's drug shortage database (posted Dec 15, 2021). Reported reason: Demand increase for the drug.